Cost-effectiveness of Merck’s potential hypertension drug will hinge on long-term data, ICER says
ICER has published a draft report on the potential cost-effectiveness of Merck’s sotatercept, a potential first-in-class fusion protein under US review as an add-on therapy for pulmonary arterial hypertension (PAH).
PAH has direct medical costs of $100,000 per person per year, according to ICER. The condition affects between 50,000 and 100,000 people in the US, and it is more common in women than in men.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.